GlaxoSmithKline
This article was originally published in The Tan Sheet
Executive Summary
NicoDerm CQ transdermal patch marketer signs development/commercialization deal with Taisho Pharmaceutical for OTC smoking cessation products in Japan. GSK will supply products, while Taisho will handle sales, distribution. Agreement comes on heels of Japan Ministry of Health's June 20 approval of Pharmacia's Nicorette gum as first OTC smoking cessation aid (1"The Tan Sheet" July 2, In Brief)
You may also be interested in...
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.